bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: O S A J J M A M F J
2016: D N O

 
  Other news for:
Neoplasms
Drug Therapy
 Resources from HONselect
Drug Combo Shows Promise Against Some Soft Tissue Tumors
Adding new drug to standard one helped control sarcomas in early trial on 2 patients

By Robert Preidt

FRIDAY, Dec. 2, 2016 (HealthDay News) -- Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates.

These cancers of soft tissues such as fat, muscles, blood vessels, tendons and ligaments are rare, but difficult to treat if they are advanced and have spread to other parts of the body, the researchers said.

"Soft tissue sarcomas represent a rare group of malignant tumors. Despite the use of surgery, radiotherapy and chemotherapy to treat the tumor in the localized region in which it started, up to 40 percent of patients will develop recurrence with cancer cells spreading to other parts of the body," said researcher Antoine Italiano. He heads the early phase trials and sarcoma units at Institut Bergonie in Bordeaux, France.

His study found that the combination of a new cancer drug called GDC-0575 with the existing cancer drug gemcitabine (Gemzar) killed soft tissue sarcoma cancer cells in laboratory and mouse studies, as well as in two patients who received the therapy in an early phase 1 clinical trial.

The patients went a longer-than-normal period without their cancer progressing, the French researchers said.

"The number of drugs approved to manage patients with advanced sarcoma is very low, and patients in this setting have a very poor outcome with a median [average] overall survival of only 12 to 18 months. Gemcitabine is one of the drugs used in patients with advanced soft tissue sarcoma," Italiano explained.

The researchers analyzed tumor samples from the first patient at the start of treatment and when the cancer started to grow again, to identify genes that might play a role in the patient's eventual resistance to the therapy.

"We have identified 16 potential [resistance] genes, and these data now have to be validated by further studies," Italiano said.

The findings were to be presented Thursday at a cancer conference in Munich, Germany. Research presented at meetings is viewed as preliminary until published in a peer-reviewed journal.

The next step is to conduct a phase 2 clinical trial to assess the safety and effectiveness of this type of combination therapy, the researchers said in a news release from the conference.

More information

The American Cancer Society has more on soft tissue sarcomas.

SOURCE: EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, news release, Dec. 1, 2016

Copyright © 2016 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=717329

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Sarcoma
Tissues
Research Personnel
Therapeutics
Specialty Chemicals and Products
Drug Therapy
Cells
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact